The Maybach Journal: CryoLife In. Review in Progress

Mar 24, 2008 (M2 PRESSWIRE via COMTEX) -- CRY | news | PowerRating | PR Charts -- MaybachFinancial.com is one of the fastest growing independent and unbiased research firms in the world. Investors wanting to know the truth about investing and how to consistently profit from whatever the markets throw our way should sign up to www.maybachfinancial.com for a free trial subscription. Through our numerous partnerships with many of the top investment minds in the world, we provide research on every company making a move in the markets. Investors seeking genuine analyst opinions on their investments for should take this opportunity to get free in-depth research on numerous publicly traded companies by becoming a member today. On Monday March 24, 2008, we have added CryoLife In. (NYSE:CRY) to the list of potential prospects.

***Please visit our site to find genuine analyst reports on numerous publicly traded companies

CryoLife Inc. was up over $0.55 on below average volume early trading Monday, March 24, 2008. They recently announced the following:

Monday, March 24, 2008 -- CryoLife, Inc., a biomaterials, medical device and tissue processing company, today announced implantation of the first CryoValve SG pulmonary human heart valve since the product was cleared by the Food and Drug Administration (FDA) in February. The procedure was performed on a patient at St. Louis Children's Hospital in St. Louis, Mo. The CryoValve SG is processed with the Company's proprietary SynerGraft technology, which removes allogeneic donor cells and cellular remnants from the valve without compromising the integrity of the underlying collagen matrix.

The CryoValve SG is indicated for the replacement of diseased, damaged, malformed or malfunctioning native pulmonary valves in pediatric and adult patients. The valve can be used in conjunction with right ventricular outflow tract reconstruction procedures (RVOT), commonly performed in children with congenital heart defects. In addition, the valve can be used for pulmonary valve replacement during the Ross Procedure, an operation in which a patient's defective aortic valve is removed and replaced with his own pulmonary valve. The CryoValve SG is then surgically implanted in place of the removed native pulmonary valve.

"CryoValve SG is an attractive valve replacement option for many children born with heart defects," said Steven G. Anderson, CryoLife's president and chief executive officer. "CryoValve SG may also be a good option for patients who underwent pulmonary valve replacement surgery at a young age, but may require another pulmonary valve replacement as they've grown into adulthood."

Charles Huddleston, M.D., chief of pediatric cardiothoracic surgery and professor of surgery at St. Louis Children's Hospital, performed the first CryoValve SG implant surgery since FDA clearance of the product in a patient who had undergone two previous allograft implants.

"The new technology provided by this SynerGraft processing was used in this patient in an effort to limit additional valve operations," said Dr. Huddleston. "We are very hopeful that this new valve will be a great thing for the patient and that the outcome with the CryoValve SG implant will last longer than the previous valve surgeries."

At the FDA's request, CryoLife is planning a post-clearance study to seek evidence for the potential and implied long-term benefits of the SynerGraft process. Data to be collected is expected to include long-term safety and hemodynamic function, immune response and explant analysis. CryoLife believes that this information may help it ascertain whether the SynerGraft process reduces the immunogenicity or potential for rejection of the transplanted heart valve and whether the valve recellularizes with the recipients own cells.

Our initial coverage of companies, updated daily, will include research in the following areas:

* Margin changes, specifically operating, gross, and then net

* The pace and quality of top line growth

* The ability to generate cash

* The pace and quality of the bottom line growth

* Market share gains

* Innovation/pipeline

* Corporate governance

* Management's ability to operate in unfavourable environments

* The ability of management to control acquisitive growth and achieve accretive results

Whether trading on the NYSE, Nasdaq, Amex, TSX or TSX-V, our highly experienced research team will investigate prime investment opportunities on behalf of the MaybachFinancial.com subscribers to offer a comprehensive look at what is happening and why. Sign up today at www.maybachfinancial.com for a free 90-day subscription.

In addition to the analyst reviews, receive a complimentary subscription to the Maybach Service and receive at no cost our "Special Report #1: Protecting Our Future,""Special Report#2: Hearing is Believing," and a new report to be released shortly. No credit card or payment information is required.

Research reports are posted prior to market open to ensure investors get the latest information, as they need it. The reports vary by sector and markets by looking at various aspects of each company in an effort to provide an unbiased view and provide pertinent information so investors can make informed decisions regarding their portfolios.

Investors can gain access to this research by signing up at www.maybachfinancial.com for a complementary 90-day trial. Sign up today to avoid missing out.

Have a company you are following? Want more in-depth information? Become a subscriber to submit your request to us via email to info@maybachfinancial.com all members' requests will be completed. It's easy, just go to www.maybachfinancial.com and sign up then email us at info@maybachfinancial.com with the subject line (stock review).

Maybach Financial (Maybach) is not a registered broker dealer or a registered investment advisor. However, we do use information from licensed analysts. No information accessed through the Maybach Web site or this release constitutes a recommendation to buy, sell or hold any security in any jurisdiction. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. There is no financial relationship that exists between the issuer of this release and the company whose stock is mentioned in the release.

Analyst reviews may or may not contain all the information listed above as each opinion and review varies with each company reviewed.

Please view the disclaimer at http://www.maybachfinancial.com/terms.php Statements made in this release may include forward-looking statements and projections, made in reliance on the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. Maybach has made every reasonable effort to ensure that the information and assumptions on which these statements and projections are based are current, reasonable, and complete. However, a variety of factors could cause actual results to differ materially from the projections, anticipated results or other expectations expressed in this release. Maybach makes these statements and projections in good faith, neither Maybach nor its management can guarantee that the transactions will be consummated or that anticipated future results will be achieved. All material herein was based upon information believed to be reliable. The information contained herein is not guaranteed by Maybach to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. Maybach assumes no obligation to publicly update or revise any forward-looking statements made herein or any other forward-looking statements made by Maybach, whether as a result of new information, future events, or otherwise.

CONTACT: Maybach Financial e-mail: info@maybachfinancial.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Morning Coffee with TradingMarkets -- Free Newsletter

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index